Also Read: GenScript and Tamarind Bio Partner to Connect AI Molecular Design with Lab Validation 

Contextualizing this paradigm shift, Anne Lecocq, Senior Vice President and General Manager, R&D, Life Sciences & Healthcare, Clarivate, said: “In modern R&D, success depends on how quickly teams can translate complex data into decisive action. Cortellis is advancing this shift with agentic AI, evolving from insight delivery to workflow execution across the product lifecycle. Together, these innovations reflect the evolution of Cortellis from a trusted information source into a connected ecosystem of agentic capabilities that augment human expertise across the R&D lifecycle. Built on trusted data, it empowers teams to reduce friction, align decisions and act with precision in high-stakes environments.” Ultimately, this strategic rollout equips global research organizations to make faster, evidence-based decisions, optimize resource allocation, and accelerate the commercialization of impactful therapeutics.

Read More: Clarivate Scales Agentic AI Across Cortellis to Advance Drug Development

The post Clarivate Expands Agentic AI Across Cortellis Portfolio to Accelerate Drug Development appeared first on ITDigest.

Also Read: Revvity Launches “Signals for Startups” to Empower Early-Stage Biotechs 

“But biology still determines what moves forward. By connecting AI-powered design to experimental proof, this partnership is helping lay the groundwork for the next generation of scientific innovation.” Underscoring the goal of democratizing computational biology and accelerating R&D timelines, “Tamarind was built to make advanced molecular design accessible to every scientist,” said Deniz Kavi, CEO and Co-Founder of Tamarind Bio. “Partnering with GenScript bridges the gap between digital design and physical experimentation, empowering scientists to turn promising candidates into actionable lab results faster than ever.” Ultimately, this connected framework empowers research teams across therapeutics and industrial biotechnology to evaluate candidate molecules faster, build higher-quality datasets, and make better-informed discovery decisions.

Read More: GenScript and Tamarind Bio Partner to Connect AI Molecular Design with Rapid Lab Validation

The post GenScript and Tamarind Bio Partner to Connect AI Molecular Design with Lab Validation appeared first on ITDigest.

Dr. Christensen brings over two decades of experience in drug discovery and development to the CEO role. Prior to joining Terremoto, he served as Chief Scientific Officer at Mirati Therapeutics, where he oversaw discovery, early clinical development, and manufacturing. He also previously held executive leadership roles at Pfizer Oncology, contributing to nonclinical research and translational science for targeted cancer therapies such as Sutent® and Xalkori®.

Also Read: CurifyLabs Raises $14M Series A to Power the Future of Personalized Medicine 

The leadership transition coincides with significant operational milestones for the South San Francisco- and San Diego-based biotechnology firm. Terremoto recently completed a $108 million Series C financing round to advance its pipeline of targeted small-molecule candidates. Additionally, the company secured FDA Fast Track designation for TER-2013, an AKT1-selective small molecule inhibitor targeting breast cancer, and filed an Investigational New Drug (IND) application for TER-4480 in Q3 2026.

Dr. Christensen’s appointment reflects Terremoto’s strategic focus on moving its proprietary pipeline through clinical development while expanding its portfolio of targeted therapeutics. With established funding, regulatory progress, and an experienced leadership team, Terremoto is positioned to accelerate its clinical-stage programs aimed at serious diseases.

The post Terremoto Biosciences Names James Christensen as Chief Executive Officer appeared first on ITDigest.

FB102, Forte Biosciences’ lead program, expands argenx’s portfolio of differentiated immunology medicines, adding a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease and potential to address multiple autoimmune diseases. The acquisition reflects argenx’s disciplined approach to identifying and advancing breakthrough science for patients with the potential to redefine standards of care in diseases that have lacked meaningful innovation for decades.

“Our Vision 2030 strategy is well-defined and on track, and our discovery, development and commercialization engines are delivering real value for patients,” said Karen Massey, Chief Executive Officer of argenx. “The acquisition of Forte Biosciences builds on the strength of that foundation and advances our ambition to be the leading immunology innovator of the future. The addition of FB102 to our portfolio aligns perfectly with the argenx playbook: compelling biology, strong clinical validation and broad potential to address patient need. I am grateful to the Forte Biosciences team for their outstanding work. Together, we look forward to unlocking the full potential of FB102 and accelerating its impact for patients.”

Also Read: Inocras and AimedBio Partner for Cancer Drug Discovery

“We are incredibly proud of what we have achieved in advancing FB102 through clinical development and firmly believe that argenx is the ideal strategic partner to unlock the full potential of this novel anti-CD122 antibody across a broad range of autoimmune diseases,” said Paul A. Wagner, Ph.D., Chief Executive Officer and Chairperson of the Board of Forte Biosciences. “By combining FB102’s promising clinical profile with argenx’s proven development expertise, global reach and commercial capabilities, we have a unique opportunity to accelerate its development and maximize its impact for patients living with vitiligo, celiac disease, alopecia areata and other autoimmune conditions. We are excited about the future of FB102 and the potential to bring this innovative therapy to many more patients worldwide.”

Forte Biosciences recently reported positive Phase 1b data in vitiligo, demonstrating statistically significant treatment benefit. In addition, positive FB102 Phase 1b data in celiac disease was shared last year, with Phase 2 data expected in the second half of this year. These studies were key drivers of argenx’s decision to move from strategic investment to acquisition, providing clinical evidence in indications with significant unmet need and limited treatment options. Beyond celiac disease and vitiligo, FB102 has the potential to address alopecia areata and additional autoimmune diseases, supporting its profile as a potential pipeline-in-a-product opportunity.

FB102 complements argenx’s existing portfolio of antibody-based programs, including efgartigimod, empasiprubart, adimanebart, and ARGX-121, as well as several additional early-stage molecules, by adding a mechanism focused on pathogenic T-cell and NK-cell activity, broadening the company’s ability to pursue diseases driven by different dimensions of the immune system.

Source: BusinessWire

The post argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline appeared first on ITDigest.

Also Read: Catalent Launches Qai to Transform Manufacturing QA

This entry-level initiative offers bundled licensing options which fit the growth pattern of companies at the pre-series and venture-backed stages, allowing start-ups to scale as their research portfolios grow without a hiccup. Highlighting the strategic value of this digital foundation for early-stage innovators, Kevin Willoe, president of Revvity Signals Software, stated: “Signals for Startups addresses a critical need for emerging biotech companies that want to move fast without creating data and workflow challenges that limit their ability to scale. By combining startup-friendly access with guided onboarding and scalable Signals workflows, we are helping early-stage teams build the digital foundation they need to advance discovery, support investor readiness and grow with confidence.” Slated for release in late July 2026 across the United States, Europe, the Middle East, and Africa, Signals for Startups empowers emerging life sciences ventures to establish robust data governance, support investor readiness, and maintain long-term competitive agility.

Read More: Revvity Launches “Signals for Startups” to Help Emerging Biotechs Build Scalable Digital Foundations from Day One

The post Revvity Launches “Signals for Startups” to Empower Early-Stage Biotechs appeared first on ITDigest.

Backed by returning and new regional and strategic investors, the round more than doubles the company’s prior raise and reflects growing conviction in both the technology and the progress behind it.

For nearly four decades, biomaterials have tried to win what surgeons and scientists call the “race for the surface,” the contest between a patient’s healing cells and bacteria to colonize a material first, by killing bacteria after they arrive.

Also Read: CurifyLabs Raises $14M Series A to Power the Future of Personalized Medicine

Auxilium takes a different approach. Its Aer platform is an engineered matrix-like product that mimics the body’s own extracellular matrix, built to win that race structurally by resisting bacterial attachment while welcoming regenerative cells, all without relying on antibiotics.

The new capital will advance the company’s lead product toward FDA clearance and into first-in-human use while deepening the team and the research behind it. Over the last year, Auxilium’s full-time team has doubled, attracting top researchers and scientists to relocate to Cleveland to join the mission.

“Last year, the question was whether the science was real. This year, it’s how fast we can get it to patients,” said Isaiah Kaiser, PhD, Founder and CEO of Auxilium Health. “We’re grateful to our investors and partners who believe in the science and the team behind what we’re building. Their confidence lets us move with the urgency this problem deserves.”

Source: PRNewswire

The post Auxilium Health Closes Oversubscribed $3.4 Million Seed Round to Advance Its Aer™ Biomaterial Platform appeared first on ITDigest.

Proceeds will be used to expand U.S. operations, strengthen supply chain infrastructure, enhance customer support, and accelerate product innovation.

CurifyLabs’ Compounding System Solution (CSS) combines proprietary software, GMP-manufactured excipient bases, and advanced 3D printing technology to automate the preparation of personalized medications. With advanced quality control processes built in, the CSS produces tailored doses and dosage forms with greater precision and speed than the manual processes typically used in pharmacies today.

Pharmacies in 21 U.S. states and across Europe use CurifyLabs technology to compound and dispense thousands of doses every day. As the company continues to scale, it will invest in its supply chain to ensure its growing network of pharmacy partners has what it needs, when it needs it.

Also Read: Inocras and AimedBio Partner for Cancer Drug Discovery

“Personalized medicine is one of the most important frontiers in healthcare enabling better patient outcomes and is experiencing solid growth. We are enabling more pharmacies to deliver personalized medicine in a safer and more efficient way,” said Morten E. Iversen, partner at Sandwater. “CurifyLabs has built something rare technology that combines clinical rigor with the speed and precision that busy pharmacy teams depend on. We are excited to support their rapid growth in the U.S. and beyond.”

“We have backed more than 136 life sciences companies over nearly three decades, and what sets the best founders apart is their ability to combine scientific depth with real-world execution,” said Daniel Karsberg, partner at HealthCap. “The CurifyLabs team has done exactly that.”

“CurifyLabs is the kind of company we want to support innovative, globally ambitious, and built on deep scientific expertise,” said Joni Karsikas, Investment Director at Tesi. “Their growth in the U.S. is further proof that Finnish health technology can compete and win on the world stage.”

“This investment reflects the conviction our partners have in what we’re building,” said Charlotta Topelius, CEO and Founder, CurifyLabs. “We have set a high bar for clinical rigor, product quality, and customer support, and this funding gives us the resources to raise that bar further.”

The funding will support ongoing development of the CurifyLabs platform, including its most recent product, the PharmaPrinter Aurum, which compounds up to nine times faster than manual processes. CurifyLabs’ technology is ISO 13485 certified and designed in compliance with FDA 503A/503B standards for non-sterile compounding.

Source: PRNewswire

The post CurifyLabs Raises $14M Series A to Power the Future of Personalized Medicine appeared first on ITDigest.

Also Read: SK bioscience Leverages AI to Optimize Global Vaccine R&D Decision-Making 

Highlighting the strategic importance of the acquisition, Fiona Marshall, President of Biomedical Research at Novartis, stated, “ADCs have become an important part of cancer treatment, but there remains a clear need for new payload mechanisms to overcome resistance and expand their impact for patients. Myricx Bio has developed a promising NMTi payload platform with a differentiated mechanism that could broaden the use of ADCs across multiple tumor settings. This proposed acquisition reflects our strategy to scale innovative platforms, as we have with radioligand therapies, to deliver more durable, transformative treatments for patients.” By targeting the NMT enzyme essential for cancer cell survival and growth, this novel mechanism hopes to overcome previous limitations and pioneer transformative cancer care.

Read More: Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients

The post Novartis Expands Oncology Pipeline with $1.1 Billion Acquisition of Myricx Bio appeared first on ITDigest.

Also Read: Boltz Partners with Takeda to Deploy Frontier Biomolecular AI Models

Initially developed and validated using rotavirus vaccine datasets from SK bioscience and PATH, the scalable platform aims to expand to other disease areas, thereby enhancing the research and development capabilities of vaccine developers in low- and middle-income countries (LMICs) while accelerating global public health equity. This initiative aligns with SK bioscience’s broader digital transformation strategy, which incorporates AI-driven experimental design systems and digital twin technologies to optimize manufacturing efficiency and shrink development timelines. Highlighting the initiative’s strategic vision, Jaeyong Ahn, CEO of SK bioscience stated, “This project represents a new approach to reducing uncertainty in vaccine development through AI and enabling more scientific and efficient decision-making. Through this consortium, we aim to drive innovation in vaccine R&D while contributing to improved vaccine access worldwide.”

Read More: SK bioscience Launches AI-Powered Initiative to Reduce Uncertainty in Vaccine-Development Decisions

The post SK bioscience Leverages AI to Optimize Global Vaccine R&D Decision-Making appeared first on ITDigest.

Strategic agreement brings Inocras’ cancer whole genome data and cancer intelligence platform into AimedBio’s ADC clinical trials, supported by a strategic equity investment

Inocras Inc., a U.S.-based precision medicine company, announced a strategic partnership with AimedBio, a South Korean biopharmaceutical company developing antibody-drug conjugates (ADCs) for cancer. As part of the agreement, AimedBio has made a strategic equity investment in Inocras, and the two companies have signed a joint research agreement to integrate Inocras’s whole genome sequencing (WGS) capabilities into AimedBio’s clinical programs.

Under the agreement, AimedBio will apply Inocras’ whole genome sequencing (WGS), cancer intelligence platform, and multi-omics analysis across its ADC clinical trials to support biomarker identification, patient selection, and novel cancer target discovery. By leveraging comprehensive cancer whole genome data, the collaboration aims to accelerate clinical development while uncovering new opportunities for precision drug discovery. The two companies also plan to explore joint commercial opportunities, connecting AimedBio’s precision drug screening business with Inocras’s diagnostic platform across global markets.

Also Read: Inocras and KAIST Launch DNAChunker for DNA Language Models 

“This partnership reflects what we’ve believed from the start, that cancer whole genome data has a role beyond diagnosing cancer. It can directly shape how new treatments are developed and identify which patients are most likely to benefit,” said Jehee Suh, CEO of Inocras. “Bringing our cancer intelligence platform into active clinical trials with AimedBio is an important step toward accelerating precision oncology and drug discovery, and we’re happy to welcome them as a strategic partner.”

Nam-Gu Her, CEO of AimedBio, said: “As ADC development grows more competitive, identifying which patients are most likely to respond to a given therapy becomes a decisive advantage. Inocras‘s genomic capabilities will support biomarker research, patient stratification, and the discovery of next-generation cancer targets, further strengthening AimedBio’s precision oncology platform.”

Source: Businesswire

The post Inocras and AimedBio Partner for Cancer Drug Discovery appeared first on ITDigest.